Loading…

3D-QSAR, Docking, ADME/Tox studies on Flavone analogs reveal anticancer activity through Tankyrase inhibition

Flavones are known as an inhibitor of tankyrase, a potential drug target of cancer. We here expedited the use of different computational approaches and presented a fast, easy, cost-effective and high throughput screening method to identify flavones analogs as potential tankyrase inhibitors. For this...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2019-04, Vol.9 (1), p.5414, Article 5414
Main Authors: Alam, Sarfaraz, Khan, Feroz
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c474t-a5a1a85bce43f7204d4a1563436c9e3a390596143b274696e54883438ec222a63
cites cdi_FETCH-LOGICAL-c474t-a5a1a85bce43f7204d4a1563436c9e3a390596143b274696e54883438ec222a63
container_end_page
container_issue 1
container_start_page 5414
container_title Scientific reports
container_volume 9
creator Alam, Sarfaraz
Khan, Feroz
description Flavones are known as an inhibitor of tankyrase, a potential drug target of cancer. We here expedited the use of different computational approaches and presented a fast, easy, cost-effective and high throughput screening method to identify flavones analogs as potential tankyrase inhibitors. For this, we developed a field point based (3D-QSAR) quantitative structure-activity relationship model. The developed model showed acceptable predictive and descriptive capability as represented by standard statistical parameters r 2 (0.89) and q 2 (0.67). This model may help to explain SAR data and illustrated the key descriptors which were firmly related with the anticancer activity. Using the QSAR model a dataset of 8000 flavonoids were evaluated to classify the bioactivity, which resulted in the identification of 1480 compounds with the IC 50 value of less than 5 µM. Further, these compounds were scrutinized through molecular docking and ADMET risk assessment. Total of 25 compounds identified which further analyzed for drug-likeness, oral bioavailability, synthetic accessibility, lead-likeness, and alerts for PAINS & Brenk. Besides, metabolites of screened compounds were also analyzed for pharmacokinetics compliance. Finally, compounds F2, F3, F8, F11, F13, F20, F21 and F25 with predicted activity (IC 50 ) of 1.59, 1, 0.62, 0.79, 3.98, 0.79, 0.63 and 0.64, respectively were find as top hit leads. This study is offering the first example of a computationally-driven tool for prioritization and discovery of novel flavone scaffold for tankyrase receptor affinity with high therapeutic windows.
doi_str_mv 10.1038/s41598-019-41984-7
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6443786</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2201701126</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-a5a1a85bce43f7204d4a1563436c9e3a390596143b274696e54883438ec222a63</originalsourceid><addsrcrecordid>eNp9kUtPGzEUhS1UBIjyB1hUlrplil8zY28qRQRoJSpEG9bWjeNMDBOb2p6I_Huchlc3eGNfnXPP9dWH0DEl3yjh8jQJWitZEaoqQZUUVbuDDhgRdcU4Y5_evffRUUp3pJyaqeLdQ_ucKM5IKw_Qko-rmz-j3yd4HMy9890JHo1_nZ9OwiNOeZg5m3Dw-KKHVfAWg4c-dAlHu7LQlzI7A97YiMFkt3J5jfMihqFb4An4-3WEZLHzCzd12QX_Ge3OoU_26Pk-RLcX55OzH9XV9eXPs9FVZUQrcgU1UJD11FjB521ZZCaA1g0XvDHKcuCK1Kqhgk9ZKxrV2FpIWVRpDWMMGn6Ivm9zH4bp0s6M9TlCrx-iW0Jc6wBO_694t9BdWOlGCN7KTcDX54AY_g42ZX0XhliWT5oxQltCKdu42NZlYkgp2vnrBEr0hpLeUtKFkv5HSbel6cv7v722vDApBr41pCL5zsa32R_EPgFoxJzF</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2201701126</pqid></control><display><type>article</type><title>3D-QSAR, Docking, ADME/Tox studies on Flavone analogs reveal anticancer activity through Tankyrase inhibition</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Alam, Sarfaraz ; Khan, Feroz</creator><creatorcontrib>Alam, Sarfaraz ; Khan, Feroz</creatorcontrib><description>Flavones are known as an inhibitor of tankyrase, a potential drug target of cancer. We here expedited the use of different computational approaches and presented a fast, easy, cost-effective and high throughput screening method to identify flavones analogs as potential tankyrase inhibitors. For this, we developed a field point based (3D-QSAR) quantitative structure-activity relationship model. The developed model showed acceptable predictive and descriptive capability as represented by standard statistical parameters r 2 (0.89) and q 2 (0.67). This model may help to explain SAR data and illustrated the key descriptors which were firmly related with the anticancer activity. Using the QSAR model a dataset of 8000 flavonoids were evaluated to classify the bioactivity, which resulted in the identification of 1480 compounds with the IC 50 value of less than 5 µM. Further, these compounds were scrutinized through molecular docking and ADMET risk assessment. Total of 25 compounds identified which further analyzed for drug-likeness, oral bioavailability, synthetic accessibility, lead-likeness, and alerts for PAINS &amp; Brenk. Besides, metabolites of screened compounds were also analyzed for pharmacokinetics compliance. Finally, compounds F2, F3, F8, F11, F13, F20, F21 and F25 with predicted activity (IC 50 ) of 1.59, 1, 0.62, 0.79, 3.98, 0.79, 0.63 and 0.64, respectively were find as top hit leads. This study is offering the first example of a computationally-driven tool for prioritization and discovery of novel flavone scaffold for tankyrase receptor affinity with high therapeutic windows.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-019-41984-7</identifier><identifier>PMID: 30932078</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>119/118 ; 631/114/2248 ; 631/114/2397 ; 631/154/570 ; 631/92/436/1729 ; 631/92/630 ; Algorithms ; Antitumor activity ; Bioavailability ; Biological activity ; Cancer ; Catalytic Domain ; Computer applications ; Cost-Benefit Analysis ; Flavones ; Flavones - chemistry ; Flavones - metabolism ; Flavones - pharmacology ; Flavonoids ; Flavonoids - chemistry ; Flavonoids - metabolism ; Flavonoids - pharmacology ; High-throughput screening ; High-Throughput Screening Assays - economics ; High-Throughput Screening Assays - methods ; Humanities and Social Sciences ; Humans ; Metabolites ; Models, Theoretical ; Molecular Docking Simulation ; Molecular Structure ; multidisciplinary ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Pharmacokinetics ; Protein Binding ; Protein Domains ; Quantitative Structure-Activity Relationship ; Risk assessment ; Science ; Science (multidisciplinary) ; Structure-activity relationships ; Tankyrases - antagonists &amp; inhibitors ; Tankyrases - chemistry ; Tankyrases - metabolism</subject><ispartof>Scientific reports, 2019-04, Vol.9 (1), p.5414, Article 5414</ispartof><rights>The Author(s) 2019</rights><rights>This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-a5a1a85bce43f7204d4a1563436c9e3a390596143b274696e54883438ec222a63</citedby><cites>FETCH-LOGICAL-c474t-a5a1a85bce43f7204d4a1563436c9e3a390596143b274696e54883438ec222a63</cites><orcidid>0000-0002-7246-8687</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2201701126/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2201701126?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25732,27903,27904,36991,44569,53769,53771,74872</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30932078$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alam, Sarfaraz</creatorcontrib><creatorcontrib>Khan, Feroz</creatorcontrib><title>3D-QSAR, Docking, ADME/Tox studies on Flavone analogs reveal anticancer activity through Tankyrase inhibition</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Flavones are known as an inhibitor of tankyrase, a potential drug target of cancer. We here expedited the use of different computational approaches and presented a fast, easy, cost-effective and high throughput screening method to identify flavones analogs as potential tankyrase inhibitors. For this, we developed a field point based (3D-QSAR) quantitative structure-activity relationship model. The developed model showed acceptable predictive and descriptive capability as represented by standard statistical parameters r 2 (0.89) and q 2 (0.67). This model may help to explain SAR data and illustrated the key descriptors which were firmly related with the anticancer activity. Using the QSAR model a dataset of 8000 flavonoids were evaluated to classify the bioactivity, which resulted in the identification of 1480 compounds with the IC 50 value of less than 5 µM. Further, these compounds were scrutinized through molecular docking and ADMET risk assessment. Total of 25 compounds identified which further analyzed for drug-likeness, oral bioavailability, synthetic accessibility, lead-likeness, and alerts for PAINS &amp; Brenk. Besides, metabolites of screened compounds were also analyzed for pharmacokinetics compliance. Finally, compounds F2, F3, F8, F11, F13, F20, F21 and F25 with predicted activity (IC 50 ) of 1.59, 1, 0.62, 0.79, 3.98, 0.79, 0.63 and 0.64, respectively were find as top hit leads. This study is offering the first example of a computationally-driven tool for prioritization and discovery of novel flavone scaffold for tankyrase receptor affinity with high therapeutic windows.</description><subject>119/118</subject><subject>631/114/2248</subject><subject>631/114/2397</subject><subject>631/154/570</subject><subject>631/92/436/1729</subject><subject>631/92/630</subject><subject>Algorithms</subject><subject>Antitumor activity</subject><subject>Bioavailability</subject><subject>Biological activity</subject><subject>Cancer</subject><subject>Catalytic Domain</subject><subject>Computer applications</subject><subject>Cost-Benefit Analysis</subject><subject>Flavones</subject><subject>Flavones - chemistry</subject><subject>Flavones - metabolism</subject><subject>Flavones - pharmacology</subject><subject>Flavonoids</subject><subject>Flavonoids - chemistry</subject><subject>Flavonoids - metabolism</subject><subject>Flavonoids - pharmacology</subject><subject>High-throughput screening</subject><subject>High-Throughput Screening Assays - economics</subject><subject>High-Throughput Screening Assays - methods</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Metabolites</subject><subject>Models, Theoretical</subject><subject>Molecular Docking Simulation</subject><subject>Molecular Structure</subject><subject>multidisciplinary</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - metabolism</subject><subject>Pharmacokinetics</subject><subject>Protein Binding</subject><subject>Protein Domains</subject><subject>Quantitative Structure-Activity Relationship</subject><subject>Risk assessment</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Structure-activity relationships</subject><subject>Tankyrases - antagonists &amp; inhibitors</subject><subject>Tankyrases - chemistry</subject><subject>Tankyrases - metabolism</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp9kUtPGzEUhS1UBIjyB1hUlrplil8zY28qRQRoJSpEG9bWjeNMDBOb2p6I_Huchlc3eGNfnXPP9dWH0DEl3yjh8jQJWitZEaoqQZUUVbuDDhgRdcU4Y5_evffRUUp3pJyaqeLdQ_ucKM5IKw_Qko-rmz-j3yd4HMy9890JHo1_nZ9OwiNOeZg5m3Dw-KKHVfAWg4c-dAlHu7LQlzI7A97YiMFkt3J5jfMihqFb4An4-3WEZLHzCzd12QX_Ge3OoU_26Pk-RLcX55OzH9XV9eXPs9FVZUQrcgU1UJD11FjB521ZZCaA1g0XvDHKcuCK1Kqhgk9ZKxrV2FpIWVRpDWMMGn6Ivm9zH4bp0s6M9TlCrx-iW0Jc6wBO_694t9BdWOlGCN7KTcDX54AY_g42ZX0XhliWT5oxQltCKdu42NZlYkgp2vnrBEr0hpLeUtKFkv5HSbel6cv7v722vDApBr41pCL5zsa32R_EPgFoxJzF</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Alam, Sarfaraz</creator><creator>Khan, Feroz</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7246-8687</orcidid></search><sort><creationdate>20190401</creationdate><title>3D-QSAR, Docking, ADME/Tox studies on Flavone analogs reveal anticancer activity through Tankyrase inhibition</title><author>Alam, Sarfaraz ; Khan, Feroz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-a5a1a85bce43f7204d4a1563436c9e3a390596143b274696e54883438ec222a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>119/118</topic><topic>631/114/2248</topic><topic>631/114/2397</topic><topic>631/154/570</topic><topic>631/92/436/1729</topic><topic>631/92/630</topic><topic>Algorithms</topic><topic>Antitumor activity</topic><topic>Bioavailability</topic><topic>Biological activity</topic><topic>Cancer</topic><topic>Catalytic Domain</topic><topic>Computer applications</topic><topic>Cost-Benefit Analysis</topic><topic>Flavones</topic><topic>Flavones - chemistry</topic><topic>Flavones - metabolism</topic><topic>Flavones - pharmacology</topic><topic>Flavonoids</topic><topic>Flavonoids - chemistry</topic><topic>Flavonoids - metabolism</topic><topic>Flavonoids - pharmacology</topic><topic>High-throughput screening</topic><topic>High-Throughput Screening Assays - economics</topic><topic>High-Throughput Screening Assays - methods</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Metabolites</topic><topic>Models, Theoretical</topic><topic>Molecular Docking Simulation</topic><topic>Molecular Structure</topic><topic>multidisciplinary</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - metabolism</topic><topic>Pharmacokinetics</topic><topic>Protein Binding</topic><topic>Protein Domains</topic><topic>Quantitative Structure-Activity Relationship</topic><topic>Risk assessment</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Structure-activity relationships</topic><topic>Tankyrases - antagonists &amp; inhibitors</topic><topic>Tankyrases - chemistry</topic><topic>Tankyrases - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alam, Sarfaraz</creatorcontrib><creatorcontrib>Khan, Feroz</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alam, Sarfaraz</au><au>Khan, Feroz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>3D-QSAR, Docking, ADME/Tox studies on Flavone analogs reveal anticancer activity through Tankyrase inhibition</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>9</volume><issue>1</issue><spage>5414</spage><pages>5414-</pages><artnum>5414</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Flavones are known as an inhibitor of tankyrase, a potential drug target of cancer. We here expedited the use of different computational approaches and presented a fast, easy, cost-effective and high throughput screening method to identify flavones analogs as potential tankyrase inhibitors. For this, we developed a field point based (3D-QSAR) quantitative structure-activity relationship model. The developed model showed acceptable predictive and descriptive capability as represented by standard statistical parameters r 2 (0.89) and q 2 (0.67). This model may help to explain SAR data and illustrated the key descriptors which were firmly related with the anticancer activity. Using the QSAR model a dataset of 8000 flavonoids were evaluated to classify the bioactivity, which resulted in the identification of 1480 compounds with the IC 50 value of less than 5 µM. Further, these compounds were scrutinized through molecular docking and ADMET risk assessment. Total of 25 compounds identified which further analyzed for drug-likeness, oral bioavailability, synthetic accessibility, lead-likeness, and alerts for PAINS &amp; Brenk. Besides, metabolites of screened compounds were also analyzed for pharmacokinetics compliance. Finally, compounds F2, F3, F8, F11, F13, F20, F21 and F25 with predicted activity (IC 50 ) of 1.59, 1, 0.62, 0.79, 3.98, 0.79, 0.63 and 0.64, respectively were find as top hit leads. This study is offering the first example of a computationally-driven tool for prioritization and discovery of novel flavone scaffold for tankyrase receptor affinity with high therapeutic windows.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>30932078</pmid><doi>10.1038/s41598-019-41984-7</doi><orcidid>https://orcid.org/0000-0002-7246-8687</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2045-2322
ispartof Scientific reports, 2019-04, Vol.9 (1), p.5414, Article 5414
issn 2045-2322
2045-2322
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6443786
source Publicly Available Content Database; PubMed Central; Free Full-Text Journals in Chemistry; Springer Nature - nature.com Journals - Fully Open Access
subjects 119/118
631/114/2248
631/114/2397
631/154/570
631/92/436/1729
631/92/630
Algorithms
Antitumor activity
Bioavailability
Biological activity
Cancer
Catalytic Domain
Computer applications
Cost-Benefit Analysis
Flavones
Flavones - chemistry
Flavones - metabolism
Flavones - pharmacology
Flavonoids
Flavonoids - chemistry
Flavonoids - metabolism
Flavonoids - pharmacology
High-throughput screening
High-Throughput Screening Assays - economics
High-Throughput Screening Assays - methods
Humanities and Social Sciences
Humans
Metabolites
Models, Theoretical
Molecular Docking Simulation
Molecular Structure
multidisciplinary
Neoplasms - drug therapy
Neoplasms - metabolism
Pharmacokinetics
Protein Binding
Protein Domains
Quantitative Structure-Activity Relationship
Risk assessment
Science
Science (multidisciplinary)
Structure-activity relationships
Tankyrases - antagonists & inhibitors
Tankyrases - chemistry
Tankyrases - metabolism
title 3D-QSAR, Docking, ADME/Tox studies on Flavone analogs reveal anticancer activity through Tankyrase inhibition
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T22%3A05%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=3D-QSAR,%20Docking,%20ADME/Tox%20studies%20on%20Flavone%20analogs%20reveal%20anticancer%20activity%20through%20Tankyrase%20inhibition&rft.jtitle=Scientific%20reports&rft.au=Alam,%20Sarfaraz&rft.date=2019-04-01&rft.volume=9&rft.issue=1&rft.spage=5414&rft.pages=5414-&rft.artnum=5414&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-019-41984-7&rft_dat=%3Cproquest_pubme%3E2201701126%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-a5a1a85bce43f7204d4a1563436c9e3a390596143b274696e54883438ec222a63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2201701126&rft_id=info:pmid/30932078&rfr_iscdi=true